Expression of Metallothioneins in Tumor Cells

Polish Journal of Pathology

Volumn 55, Issue 1, 2004, Pages 3-12

  Dziȩgiel, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTHRACYCLINE DERIVATIVE; ANTIBODY; ANTINEOPLASTIC AGENT; BINDING PROTEIN; CADMIUM; CARBOPLATIN; CISPLATIN; COPPER; CYCLINE; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FREE RADICAL; GLUCOCORTICOID; GLUTATHIONE TRANSFERASE; INTERFERON; KI 67 ANTIGEN; LEAD; LYSINE; MERCURY; MESSENGER RNA; METAL ION; METALLOTHIONEIN; MULTIDRUG RESISTANCE PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; THIOL GROUP; UNINDEXED DRUG; ZINC;

BRAIN TUMOR; BREAST CARCINOMA; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; GALLBLADDER CARCINOMA; GASTROINTESTINAL CARCINOMA; GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY CARCINOMA; LIVER CANCER; MOUTH TUMOR; NONHUMAN; OVARY CANCER; PANCREAS TUMOR; PROGNOSIS; PROTEIN EXPRESSION; RADIOIMMUNOLOGY; RESPIRATORY TRACT TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SARCOMA; STOMACH CARCINOMA; TESTIS TUMOR; TUMOR CELL; UROGENITAL TRACT TUMOR; UTERUS CARCINOMA;

ANIMALS; FEMALE; HUMANS; MALE; METALLOTHIONEIN; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 2342458182     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Barnes NL, Ackland ML, Cornish EJ: Metallothionein isoform expression by breast cancer cells. Int J Biochem Cell Biol 2000, 32, 895-903.
2. Beyersmann D, Haase H: Functions of zinc in signaling, proliferation and differentiation of mammalian cells. BioMetals 2001, 14, 331-341.
3. Boon-Huat B, Jin R, Jayasurya A: Analysis of metallothionein expression in human cancers. Acta Histochem Cytochem 2001, 34, 171-176.
4. Bruewer M, Schmid KW, Krieglstein CF, Senninger N, Schuermann G: Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma. World J Surg 2002, 26, 726-731.
5. Bruewer M, Schmid KW, Metz KA, Krieglstein CF, Senninger N, Schuermann G: Increased expression of metallothionein in inflammatory bowel disease. Inflamm Res 2001, 50, 289-293.
6. Cardoso SV, Barbosa HM, Candelloriim IM, Loyola AM, Aguiar MCF: Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch 2002, 441, 174-178.
7. Cherian MG, Apostolova MD: Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol 2000, 46, 347-356.
8. Coyle P, Philcox JC, Carey LC, Rofe AM: Metallothionein: The multipurpose protein. Cell Mol Life Sci 2002, 59, 627-647.
9. Deng DX, Chakrabarti S, Waalkes M, Cherian MG: Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma. Histopathology 1998, 32, 340-347.
10. Deugnier MA, Teuliere J, Faraldo MM, Thiery JP, Glukhova MA: The importance of being a myoepithelial cell. Breast Cancer Res 2002, 4, 224-230.
11. Dziȩgiel P, Forgacz J, Suder E, Surowiak P, Kornafel J, Zabel M: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 2003, 18, 401-407.
12. Dziȩgiel P, Suder E, Surowiak P, Kornafel J, Zabel M: Expression of metallothionein in synovial sarcoma cells. Appl Immunohistochem Mol Morphol 2002, 10, 357-363.
13. Ebert MPA, Gnther T, Hoffmann J, YU J, Miehlke S, Schulz HU, Roessner A, Korc M, Malfertheiner P: Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res 2000, 60, 1995-2001.
14. Eid H, Geczi L, Bodrogi I, Institoris E, Bak M: Do metallothioneins affect the response to treatment in testis cancers? J Cancer Res Clin Oncol 1998, 124, 31-36.
15. Elis O, Pinder SE, Lee AHS, Elston CW: Tumors of the breast. In: Diagnostic Histopathology of Tumors. Fletcher CDM, ed. Churchill Livingstone, London, Edinburgh, New York, Philadelphia, St Louis, Sydney, Toronto 2000, 865-930.
16. Floriańczyk B, Grzybowska L: Metallothionein levels in cell fraction from breast cancer tissues. Acta Oncol 2000, 39, 141-143.
17. Gaumann A, Tews DS, Mentzel T, Petrow PK, Mayer E, Otto M, Kirkpatrick CJ, Kriegsmann J: Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of the other origin. Virchows Arch 2003, 442, 529-537.
18. Goldmann T, Moorkamp A, Wiedorn KH, Suter L, Otto F: The prognostic value of the expression of collagenase IV, cathepsin D and metallothionein in squamous cell carcinomas of the skin determined by immunohistochemistry. Arch Dermatol Res 2001, 293, 115-120.
19. Han KH, Huh CH, Cho KH: Proliferation and differentiation of the keratinocytes in hyperplastic epidermis overlying dermatofibroma. Am J Dermatopathol 2001, 23, 90-98.
20. Hengstler JG, Pilch H, Schmidt M, Dahlenburg H, Sagemüller J, Schiffer I, Oesch F, Knapstein PG, Kaina B, Tanner B: Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer 2001, 95, 121-127.
21. Hishikawa Y, Kohno H, Ueda S, Kimoto T, Dhar DK, Kubota H, Tachibana M, Koji T, Nagasue N: Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology 2001, 61, 162-167.
22. Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, Nagasue N: Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 1999, 81, 712-720.
23. Huang GW, Yang LY: Metallothionein expression in hepatocellular carcinoma. World J Gastroenterol 2002, 8, 650-653.
24. Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A, Agnantis NJ: Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract 1999, 195, 809-814.
25. Ioachim E, Goussia AC, Agnantis NJ, Machera M, Tsianos EV, Kappas AM. Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J Clin Pathol 1999, 52, 876-879.
26. Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D, Agnantisn N: Immunohistochemical localization of metallothionein in human breast cancer in comparision with cathepsin D, stromelysin-1, CD44, extracellular matrix components, p53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res 1999, 19, 2133-2140.
27. Ioachim EE, Charchanti AV, Stavropoulos NE, Athanassiou ED, Michael MC, Agnantis NJ: Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices. Anticancer Res 2001, 21, 1757-1762.
28. Ioachim EE, Kitsiou E, Carassavoglou C, Stefanaki S, Agnantis NJ: Immunohistochemical localization of metallothionein in endometrial lesions. J Pathol 2000, 191, 269-273.
29. Isik R, Metintas M, Gibbs AR, Metintas S, Jasani B, Oner U, Harmanci E, Demircan S, Isiksoy S: p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir Med 2001, 95, 588-593.
30. Janssen AML, Van Dujin W, Kubben FJ, Griffioen G, Lamers CBHW, Van Krieken JHJM, Van De Velde CJH, Verspaget HW: Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 2002, 8, 1889-1896.
31. Janssen AML, Van Dujin W, Oostendorp-Van De Ruit MM, Kruidenier L, Bosman CB, Griffioen G, Lamers CBHW, Van Krieken JHJM, Van De Velde CJH, Verspaget HW: Metallothionein in human gastrointestinal cancer. J Pathol 2000, 192, 293-300.
32. Jayasurya A, Bay BH, Yap WM, Tan NG, Tan BKH: Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis 2000, 21, 1809-1812.
33. Jayasurya A, Bay BH, Yap WM, Tan NG: Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br J Cancer 2000, 82, 1198-1203.
34. Jin R, Bay BH, Chow VT, Tan PH, Dheen T: Significance of metallothionein expression in breast myoepithelial cells. Cell Tissue Res 2001, 303, 221-226.
35. Jin R, Bay BH, Chow VT, Tan PH, Lin VC: Metallothionein 1E mRNA is highly expressed in estrogen receptor-negative human invasive ductal breast cancer. Br J Cancer 2000, 83, 319-323.
36. Jin R, Bay BH, Chow VT, Tan PH: Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Cancer Res Treat 2001, 66, 265-272.
37. Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH: Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002, 23, 81-86.
38. Joseph MG, Banerjee D, Kocha W, Feld R, Stitt LW, Cherian MG: Metallothionein expression in patients with small cell carcinoma of the lung. Cancer 2001, 92, 836-842.
39. Kishi K, Doki Y, Miyata H, Yano M, Yasuda T, Monden M: Prediction of the response to chemoradiation and prognosis in esophageal squamous cancer. Br J Surg 2002, 89, 597-603.
40. Korshunov A, Golanov A, Sycheva R, Pronin I, Fadeeva L: Prognostic value of the immunoexpression of chemoresistance-related proteins in cerebral glioblastomas: an analysis of 168 cases. Neuropathol 1999, 19, 143-149.
41. Lele SM, Graves KMT, Gatalica Z: Immunohistochemical detection of maspin is a useful adjunct in distinguishing radial sclerosing lesion from tubular carcinoma of the breast. Appl Immunohistochem Mol Morphol 2000, 8, 32-36.
42. Lynn NNK, Howe MC, Have RJ, Collins GN, O'Reilly PH: Overexpression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy. J Urol 2003, 169, 721-723.
43. Mattern J, Koomägi R, Volm M: Expression of drug resistance gene products during progression of lung carcinomas. Oncol Rep 2002, 9, 1181-1184.
44. McCluggage WG, Maxwell P, Hamilton PW, Jasani B: High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 1999, 34, 51-55.
45. McCluggage WG, Strand K, Abdulkadir A: Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer 2002, 12, 62-65.
46. Moran CA, Suster S: Tumors of the lung and pleura. In: Diagnostic Histopathology of Tumors. Fletcher CDM, ed. Churchill Livingstone, London, Edinburgh, New York, Philadelphia, St Louis, Sydney, Toronto 2000, 171-208.
47. Naguyen A, Jing Z, Mahoney PS, Davis R, Sikka SC, Agrawal KC, Abdel-Mageed AB: In vivo gene expression profile analysis of metallothionein in renal cell carcinoma. Cancer Lett 2000, 160, 133-140.
48. Paraskevakou H, Theocharis SE, Tseleni S, Athanasiades A, Davaris PS: Expression of metallothionein in renal cell carcinoma: an immunohistochemical study. Lab Invest 1999, 79, 103.
49. Romero-Isart N, Vak M: Advances in the structure and chemistry of metallothioneins. J Inorg Biochem 2002, 88, 388-396.
50. Saga Y, Hashimoto H, Yachiku S, Tokumitsu M, Kaneko S: Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patient survival. J Urol 2002, 168, 2227-2231.
51. Satoh M, Naganuma A, Imura N: Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci 2000, 67, 627-634.
52. Sens MA, Somji S, Garrett SH, Beall CL, Sens D: Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 2001, 159, 21-26.
53. Shukla VK, Aryya NC, Pitale A, Pandey M, Dixit VK, Reddy CD, Gautam A: Metallothionein expression in carcinoma of the gallbladder. Histopathology 1998, 33, 154-157.
54. Siegsmud MJ, Marx C, Seemann O, Schummer B, Steidler A, Toktomambetova L, Kohrmann KU, Rassweiler J, Alken P: Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothionein. Urol Res 1999, 27, 157-163.
55. Simpkins CO: Metallothionein in human disease. Cell Mol Biol 2000, 46, 465-488.
56. Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA: Metallothionein isoform I and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev 2001, 25, 62-75.
57. Stenram U, Ohlsson B, Tranberg KG: Immunohistochemical expression of metallothionein in resected hepatic primary tumors and colorectal carcinoma metastases. APMIS 1999, 107, 420-424.
58. Sugita K, Yamamoto O, Asahi M: Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am J Dermatopathol 2001, 23, 29-35.
59. Surowiak P, Dziȩgiel P, Matkowski R, Wojnar A, Kornafel J, Zabel M: Significance of metallothionein (MT) expression in tumor and myoepithelial cells in structures of ductal breast carcinoma. (submitted).
60. Sutoh I, Kohno H, Nakashima Y, Hishikawa Y, Tabara H, Tachibana M, Kubota H, Nagasue N: Concurrent expressions of metallothionein, glutathion s-transferase-[pi], and P-glycoprotein in colorectal cancers. Dis Colon Rectum 2000, 43, 221-232.
61. Szilgyi Z, Fenselau C: Molecular dynamics simulation of metallothionein-drug complexes. Drug Metab Dispos 2000, 2, 174-179.
62. Tan YI, Sinniah R, Bay BH, Singh G: Expression of metallothionein and nuclear size in discrimination of malignancy in mucinous ovarian tumors. Int. J Gynecol Pathol 1999, 18, 344-350.
63. Tan YI, Sinniah R, Bay BH, Singh G: Metallothionein expression and nuclear size in benign, bordeline, and malignant serous ovarian tumors. J. Pathol 1999, 189, 60-65.
64. Tews DS, Fleissner C, Tiziani B, Gaumann AKA: Intrinsic expression of drug resistance-associated factors in meningiomas. Appl Immunohistochem Mol Morphol 2001, 9, 242-249.
65. Theocharis S, Karkantaris C, Philipides T, Agapitose A, Gika A, Margeli A, Kittas C, Koutselinis A: Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology 2002, 40, 143-151.
66. Tomita T: Metallothionein in pancreatic endocrine neoplasms. Mod Pathol 2000, 13, 389-395.
67. Trieb K, Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 2001, 33, 11-17.
68. Tuccari G, Giuffre G, Arena F, Baresi G: Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa. Histol Histopathol 2000, 15, 1035-1041.
69. Tüzel E, Kirkali Z, Yorukoglu K, Mungan MU, Sade M: Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. J Urol 2001, 165, 1710-1713.
70. Vak M, Hasler DW: Metallothioneins: new functional and structural insights. Curr Opin Chem Biol 2000, 4, 177-183.
71. Vazquez-Ramirez FJ, Gonzalez-Campora JJ, Hevia-Alvarez E, Fernadez-Santos JM, Rios-Martin JJ, Otal-Salaverri C, Gonzalez-Campora R: P-glycoprotein, metallothionein and NM23 protein expression in breast carcinoma. Pathol Res Pract 2000, 196, 553-559.
72. Volm M, Koomägi R, Mattern J, Efferth T: Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer 2002, 87, 251-257.
73. Wirgley E, Verspaget HW, Jayson GC, McGown AT: Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 2000, 126, 717-721.
74. Wronkowski Z, Zwierko M: Epidemiology, risk factors and potential for bypassing them (in Polish). In: Nowotwory jelita grubego. Nowacki MP, ed. Wydawnictwo Wiedza i Życie, Warszawa 1996, 24-50.
75. Zhang R, Zhang H, Wei H, Luo X: Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. J Environ Pathol Toxicol Oncol 2000, 19, 95-97.
76. Zhang XH, Takenaka I: Incidence of apoptosis and metallothionein expression in renal cell carcinoma. Br J Urol 1998, 81, 9-13.